Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
Rohit ThummalapalliBiagio RicciutiChaitanya BandlamudiDaniel M MuldoonHira A RizviArielle ElkriefJia LuoJoao M Victor AlessiFederica PecciGiuseppe LambertiAlessandro Di FedericoLingzhi HongJianjun ZhangJohn Victor HeymachDon L GibbonsAndrew J PlodkowskiVignesh RavichandranMark T A DonoghueChad M VanderbiltMarc LadanyiCharles M RudinMark G KrisGregory J RielyJamie E ChaftMatthew D HellmannNatalie I VokesMark M AwadAdam J SchoenfeldPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Among advanced NSCLC patients treated with ICIs, distinct features including high TMB, non-squamous histology, and depth of radiographic improvement distinguish patients poised to achieve long-term response compared to initial response followed by progression, whereas high PD-L1 does not.